Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cybersecurity Forum: Trustworthiness, Threat Modeling Central Issues

Executive Summary

US FDA hosted a range of device- and IT-industry stakeholders for a two-day event on medical device cybersecurity in pre-market submissions. The first day emphasized securing legacy software, authentication and encryption techniques, and risk assessment models, among other issues

You may also be interested in...



US Homeland Security: Stryker, BD Devices Pose Hacking Risk

The US Department of Homeland Security National Cybersecurity and Communications Integration Center is warning of potential cybersecurity vulnerabilities in Stryker hospital beds and BD diagnostics equipment.

FDA Cybersecurity Forum: Manufacturers Explain Coordinated Vulnerability Disclosures

Device firms well-versed in carrying out coordinated vulnerability disclosures said it is important to secure company executive buy-in and to use the principles laid out in an evolving US FDA guidance on cybersecurity for assistance at a recent FDA cybersecurity meeting.

Device-Makers Need To Open Up More On Cybersecurity In Pre-Market, Draft Guidance Says

A new update to the pre-market cybersecurity guidance issued four years ago reflects how US FDA's thinking on the issue has evolved, as more cases of device vulnerabilities have surfaced. Among the key updates are recommendations for sponsors to submit a cybersecurity "bill of materials" in product labeling to better coordinate with end-users and to use a two-tiered risk management approach.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel